These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21246591)

  • 1. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis.
    Pettengell R; Schwenkglenks M; Bacon P; Lawrinson S; Duehrsen U
    Hematol Oncol; 2011 Dec; 29(4):177-84. PubMed ID: 21246591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
    Balducci L; Mo M; Abella E; Saven A
    Am J Clin Oncol; 2014 Dec; 37(6):603-10. PubMed ID: 25350463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
    Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim.
    Ng JH; Ang XY; Tan SH; Tao M; Lim ST; Chan A
    Acta Haematol; 2011; 125(3):107-14. PubMed ID: 21109731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
    Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
    J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
    Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
    J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study.
    Fiegl M; Steger GG; Studnicka M; Eisterer W; Jaeger C; Willenbacher W
    Curr Med Res Opin; 2013 May; 29(5):505-15. PubMed ID: 23444969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
    Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
    BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
    Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
    Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
    Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
    Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
    Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
    Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G; Lalla A; Barron R; Dubois RW
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.
    Lee S; Knox A; Zeng IS; Coomarasamy C; Blacklock H; Issa S
    Support Care Cancer; 2013 Mar; 21(3):841-6. PubMed ID: 22972488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
    Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
    Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH; Delgado DJ
    Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.